NASDAQ · ATOS
Healthcare · Biotechnology
$2.42
Down-$0.02 (-0.67%)
Updated Sep 17, 2026, 7:27 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ATOS closed at $2.42 after 20 trading sessions, down 8.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $2.39 | $2.48 | $2.39 | $2.42 | 45.78K |
| Sep 15, 2026 | $2.475 | $2.49 | $2.37 | $2.37 | 43.78K |
| Sep 14, 2026 | $2.53 | $2.555 | $2.45 | $2.48 | 35.04K |
| Sep 11, 2026 | $2.36 | $2.54 | $2.36 | $2.51 | 60.41K |
| Sep 10, 2026 | $2.36 | $2.61 | $2.33 | $2.34 | 47.24K |
| Sep 9, 2026 | $2.54 | $2.54 | $2.40 | $2.40 | 24.8K |
| Sep 8, 2026 | $2.49 | $2.5871 | $2.4446 | $2.515 | 41.37K |
| Sep 4, 2026 | $2.51 | $2.60 | $2.50 | $2.52 | 28.03K |
| Sep 3, 2026 | $2.50 | $2.60 | $2.46 | $2.53 | 56.69K |
| Sep 2, 2026 | $2.40 | $2.51 | $2.39 | $2.46 | 44.77K |
| Sep 1, 2026 | $2.48 | $2.50 | $2.317 | $2.42 | 92K |
| Aug 31, 2026 | $2.57 | $2.5895 | $2.50 | $2.50 | 53.19K |
| Aug 28, 2026 | $2.62 | $2.62 | $2.50 | $2.58 | 49K |
| Aug 27, 2026 | $2.64 | $2.69 | $2.5848 | $2.64 | 23.12K |
| Aug 26, 2026 | $2.66 | $2.70 | $2.61 | $2.65 | 26.3K |
| Aug 25, 2026 | $2.62 | $2.69 | $2.58 | $2.68 | 49.69K |
| Aug 24, 2026 | $2.56 | $2.65 | $2.45 | $2.64 | 57.15K |
| Aug 21, 2026 | $2.59 | $2.62 | $2.51 | $2.54 | 25.66K |
| Aug 20, 2026 | $2.62 | $2.62 | $2.44 | $2.59 | 70.95K |
| Aug 19, 2026 | $2.57 | $2.76 | $2.55 | $2.64 | 62.2K |
The latest Smart Investors Daily articles mentioning ATOS.
ATOS research
Company profile and research snapshot.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 7, 2026 | Rodman & Renshaw | Buy | — |
| Apr 10, 2026 | Ascendiant Capital | Buy | — |
| Mar 26, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 8, 2025 | Ascendiant Capital | Buy | — |
| Sep 22, 2025 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.02) by 6.86 percent. This is a 171.43 percent decrease over losses of $(0.35) per share
Benzinga · Jul 28, 2026
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant modelsFindings suggest potential for combination with abemaciclibSEATTLE, July 28, 2026
Benzinga · Jul 21, 2026
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndromeSEATTLE, July 21, 2026 /PRNewswire/
Benzinga · Jul 7, 2026
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $12.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ATOS.
